AsiaNet 94577

スミス・アンド・ネフューは、次世代型ロボット支援手術システム「CORI」発売しました。新しいタイプの骨切除用器械を導入することで骨切除に掛かる時間を短くすることができ、[1-4]手術時間の短縮も期待できます。[5-6]

ロンドン , 2022年2月21日 /PRNewswire-AsiaNet/ -- スミス・アンド・ネフュー株式会社（本社：東京都港区、代表取締役社長：土橋慎也）は、2021年7月に「CORI <Core of Real Intelligence>」（販売名：CORI サージカルシステム）の薬事承認を取得し、10月から販売を開始致しました。

写真 - https://mma.prnewswire.com/media/1749389/Japan_social_2_CORI.jpg

ロゴ - https://mma.prnewswire.com/media/3924/smith.jpg

CORI <コリ>は2012年から世界各国で使用されている「NAVIO <ナビオ>」（販売名：NAVIO ロボット支援手術システム）の次世代機として開発されました。2020-2027年の間、整形外科分野のロボット支援手術の市場を年平均成長率37.3%と推測されています。[7]

NAVIOのノウハウを踏襲しつつ、新しいタイプの骨切除用器械を導入することで骨切除に掛かる時間を短くすることができ、手術時間の短縮も期待できます。[8]また、CORI専用のハンドピースは骨切除の位置や量がシステムにて制御され、更には新しい赤外線カメラの導入によって位置情報の認識スピードが向上することでより安全かつ正確な手術が期待できます。[9]

「日本におけるロボット手術の需要の高まりに応える立場にあり、CORI外科システムの発売を発表できることをうれしく思います。私たちは、高度な性能を備えたこのエキサイティングな技術を通じて、外科医や患者に多くの利益をもたらすことを願っています。」（スミス・アンド・ネフュー株式会社、代表取締役、土橋慎也）

患者様個々の膝の状態を手術中にシステムへ読み込ませることで、オーダーメイドな手術をサポートいたします。[10]また、前十字靭帯及び後十字靭帯共に温存する両十字靭帯温存型人工膝関節置換術にも対応しており、患者様の要望もしくは膝の状態に適した人工膝関節システムを提供することが可能となりますので、術後のQOL(クオリティオブライフ)の更なる向上も期待できます。[11]

スミス・アンド・ネフューについて
スミス・アンド・ネフューは、様々なテクノロジーを活用して、人々の生活の質の向上に貢献できるように努めています。私たちはこれを"Life Unlimited"と呼んでいます。全世界18,000人の従業員がこのミッションに日々取り組み、整形外科や創傷治療分野、スポーツ整形外科、耳鼻咽喉科領域における新しい技術の開発、そしてその発展を通じて、患者様の生活に貢献しています。
1856年に英国のHullで創立され、現在では100ヵ国以上で事業を展開し、2020年の売上高は46億ドルでした。また、FTSE100 (LSE: SN, NYSE: SNN)の中の1社でもあります。

参考文献

References

1. Kopjar B, Schwarzkopf R, Chow J, et al. NAVIO Robotic Assisted Surgical System for Total Knee Arthroplasty Using JOURNEY II Guided-Motion Total Knee System. Poster presented at: ISTA 2-5 October, 2019; Toronto, Canada.

2. Geller JA, Rossington A, Mitra R, Jaramaz B, Khare R, Netravali NA. Rate of learning curve and alignment accuracy of an image-free handheld robot for total Knee Arthroplasty. European Knee Society Arthroplasty Conference;2019; Valencia, Spain.

3. Battenberg AK, Netravali NA, Lonner JH. A novel handheld robotic-assisted system for unicompartmental knee arthroplasty: surgical technique and early survivorship. J Robot Surg. 2019;14(1):55-60.

4. Picard F, Gregori A, Bellemans J, et al. Handheld Robot-Assisted Unicondylar Knee Arthroplasty: A Clinical Review. Poster presented at: Computer Assisted Orthopaedic Surgery (CAOS) 14th Annual Meeting;October, 2014; Milan, Italy

5. Shearman A, Sephton BM, Nathwani D. Robotic-assisted unicondylar knee arthroplasty is associated with earlier discharge from physiotherapy and reduced length of stay compared to conventional navigated techniques. European Knee Society Arthroplasty Conference;2019; Valencia, Spain

6. Canetti R, Batailler C, Bankhead C, Neyret P, Servien E, Lustig S. Faster return to sport after robotic-assisted lateral unicompartmental knee arthroplasty: a comparative study. Arch Orthop Trauma Surg. 2018;138(12):1765-1771.

7. https://www.reportlinker.com/p05957605/Global-Orthopedic-Surgical-Robots-Industry.html?utm_source=GNW (Accessed: 15th Dec 2021)

8. Smith+Nephew 2020. Comparison of operating room footprint for robotic-assisted knee arthroplasty systems. Internal Report. EO.REC.PCS015.002.v1.

9. Smith+Nephew 2019. Implant Placement Accuracy Verification. Internal Report. TR1521

10. Smith+Nephew 2020. CORI◊ and NAVIO◊ Technical Specification Comparison. Internal Report. ER0488 REV B.

11. Predictors of extended length of stay after unicompartmental knee arthroplasty. J Clin Orthop Trauma. 2019

承認番号：30300BZX00186000
販売名：CORI サージカルシステム
承認番号：23000BZX00377000
販売名：NAVIO ロボット支援手術システム

本件に関するお問い合わせ先
スミス・アンド・ネフュー（株） オーソペディックス事業部 
E-mail: Navio.JP@smith-nephew.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

(TM) Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

ソース Smith & Nephew plc

（日本語リリース：クライアント提供）